In-vitro Synergistic Effect of Metformin and Berberine on High Glucose-induced Lipogenesis

Document Type : Research article

Authors

Department of Clinical Biochemistry, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran.

Abstract

Metformin and berberine have been reported to have lipid lowering effects. This study aims to investigate lipid lowering effects of berberine and metformin, alone and in combination, in HepG2 cells to determine whether berberine and metformin work synergistically and elucidate their mechanisms. HepG2 cells were treated with 33 mM glucose in the presence of various concentrations of berberine and metformin, alone and in combination, for 24 h. The cytotoxic effects of these compounds were determined by MTT assay. Oil red O staining, triglyceride measurement, and gene expression analyses were performed to evaluate the effects of these compounds on hepatocytes lipogenesis. Berberine at doses 20 µM and 40 µM and metformin at doses 1 mM  and 2 mM reduced total lipid content and triglyceride level in HepG2 cells. Metformin (mM) and berberine (µM) at combination ratios of 2:40, 1:20, 0.5:10, and 0.25:5 exhibited a synergistic lipid-lowering effect on HepG2 cells. These ratios could significantly decrease total lipid content and triglyceride level in HepG2 cells. The lowest dose of the combination [metformin (0.25 mM) and berberine (5 μM)] also synergistically reduced the expression of the FAS and SREBP-1c genes in HepG2 cells treated with high glucose. The combination of metformin and berberine exerted synergistic lipid-lowering effects on HepG2 cells by reducing total lipid content, triglyceride level, and the expression of the genes involved in lipogenesis.

Keywords

Main Subjects


References
Whiting DR, Guariguata L, Weil C and Shaw J. IDF
diabetes atlas: global estimates of the prevalence of
diabetes for 2011 and 2030. Diabetes Res. Clin. Pract.
(2011) 94: 311-21.
Khodabandehloo H, Gorgani-Firuzjaee S, Panahi G
and Meshkani R. Molecular and cellular mechanisms
linking inflammation to insulin resistance and β-cell
dysfunction. Transl. Res. (2016) 167: 228-56.
Meshkani R and Adeli K. Hepatic insulin resistance,
metabolic syndrome and cardiovascular disease. Clin.
Biochem. (2009) 42: 1331-46.
Lin MC, Gordon D and Wetterau JR. Microsomal
triglyceride transfer protein (MTP) regulation in
HepG2 cells: insulin negatively regulates MTP gene
expression. J. Lipid Res. (1995) 36: 1073-81.
Reaven GM and Mondon CE. Effect of in-vivo plasma
insulin levels on the relationship between perfusate
free fatty acid concentration and triglyceride secretion
by perfused rat livers. Horm. Metab. Res. (1984) 16:
230-2.
Xu X, So JS, Park JG and Lee AH. Transcriptional
control of hepatic lipid metabolism by SREBP and
ChREBP. Semin. Liver Dis. (2013) 33: 301-11
Diabetes Prevention Program Research Group.
Reduction in the incidence of type 2 diabetes with
lifestyle intervention or Metformin. N. Engl. J. Med.
(2002) 346: 393-403.
Portillo-Sanchez P and Cusi K. Treatment of
nonalcoholic fatty liver disease (NAFLD) in patients
with type 2 diabetes mellitus. Clin. Diabetes
Endocrinol. (2016) 2: 9.
Garber AJ, Duncan TG, Goodman AM, Mills DJ and
Rohlf JL. Efficacy of Metformin in type II diabetes:
results of a double-blind, placebo-controlled, doseresponse trial. Am. J. Med. (1997) 103: 491-7.
Okayasu S, Kitaichi K, Hori A, Suwa T, Horikawa Y,
Yamamoto M, Takeda J and Itoh Y. The evaluation of
risk factors associated with adverse drug reactions by
Metformin in type 2 diabetes mellitus. Biol. Pharm.
Bull. (2012) 35: 933-7.
Turner RC, Cull CA, Frighi V and Holman RR.
Glycemic control with diet, sulfonylurea, Metformin,
or insulin in patients with type 2 diabetes mellitus:
progressive requirement for multiple therapies
(UKPDS 49). UK Prospective Diabetes Study
(UKPDS) Group. JAMA (1999) 281: 2005-12.
Vuddanda PR, Chakraborty S and Singh S. Berberine:
a potential phytochemical with multispectrum
therapeutic activities. Expert Opin. Investig. Drugs.
(2010) 19: 1297-307.
Firdous SM. Phytochemicals for treatment of diabetes.
EXCLI J. (2014) 13: 451-3.
Panahi G, Pasalar P, Zare M, Rizzuto R and Meshkani
R. High glucose induces inflammatory responses
in HepG2 cells via the oxidative stress-mediated
activation of NF-κB, and MAPK pathways in HepG2
cells. Arch. Physiol. Biochem. (2018) 124: 468-74.
(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
(11)
(12)
(13)
(14)
Lambert JE, Ramos-Roman MA, Browning JD and
Parks EJ. Increased de novo lipogenesis is a distinct
characteristic of individuals with nonalcoholic fatty
liver disease. Gastroenterology (2014) 146: 726-35.
Fullerton MD, Galic S, Marcinko K, Sikkema S,
Pulinilkunnil T, Chen ZP, O′Neill HM, Ford RJ,
Palanivel R, O′Brien M, Hardie DG, Macaulay SL,
Schertzer JD, Dyck JR, van Denderen BJ, Kemp BE
and Steinberg GR. Single phosphorylation sites in
Acc1 and Acc2 regulate lipid homeostasis and the
insulin–sensitizing effects of Metformin. Nat. Med.
(2013) 19: 1649-54.
Savage DB, Petersen KF and Shulman GI. Disordered
lipid metabolism and the pathogenesis of insulin
resistance. Physiol. Rev. (2007) 87: 507-20.
Wilke MS, French MA, Goh YK, Ryan EA, Jones PJ
and Clandinin MT. Synthesis of specific fatty acids
contributes to VLDL-triacylglycerol composition in
humans with and without type 2 diabetes. Diabetologia
(2009) 52: 1628-37.
Marques-Lopes I, Ansorena D, Astiasaran I, Forga L
and Martinez JA. Postprandial de novo lipogenesis and
metabolic changes induced by a high-carbohydrate,
low-fat meal in lean and overweight men. Am. J. Clin.
Nutr. (2001) 73: 253-61.
Viollet B, Guigas B, Garcia NS, Leclerc J, Foretz M
and Andreelli F. Cellular and molecular mechanisms
of Metformin: an overview. Clin. Sci. (2012) 122:
253-70.
Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G
and Diehl AM. Metformin reverses fatty liver disease
in obese, leptin-deficient mice. Nat. Med. (2000) 6:
998-1003.
Hookman P and Barkin JS. Current biochemical studies
of nonalcoholic fatty liver disease and nonalcoholic
steatohepatitis suggest a new therapeutic approach.
Am. J. Gastroenterol. (2003) 98: 2093-7.
Gao ZQ, Lu FE, Dong H, Xu LJ, Wang KF and Zhou
X. Study on therapeutic effects of Metformin on rat
fatty livers induced by high fat feeding. Zhonghua Gan
Zang Bing Za Zhi (2005) 13: 101-4.
Chen SQ, Liu Q, Sun H, Tang L and Deng JC. Effects
of Metformin on fatty liver in insulin-resistant rats.
Zhonghua Gan Zang Bing Za Zhi (2005) 13: 915-8.
Idilman R, Mizrak D, Corapcioglu D, Bektas M,
Doganay B, Sayki M, Coban S, Erden E, Soykan
I, Emral R, Uysal AR and Ozden A. Clinical trial:
insulin‐sensitizing agents may reduce consequences
of insulin resistance in individuals with non‐alcoholic
steatohepatitis. Aliment. Pharmacol. Ther. (2008) 28:
200-8.
Li Y, Liu L, Wang B, Wang J and Chen D. Metformin in
non-alcoholic fatty liver disease: A systematic review
and meta‑analysis. Biomed. Rep. (2013) 1: 57-64.
Bruckbauer A and Zemel MB. Synergistic effects of
Metformin, resveratrol, and hydroxymethylbutyrate
on insulin sensitivity. Diabetes Metab. Syndr. Obes.
(2013) 6: 93-102.
Hu Y, Ehli EA, Kittelsrud J, Ronan PJ, Munger K,
(15)
(16)
(17)
(18)
(19)
(20)
(21)
(22)
(23)
(24)
(25)
(26)
(27)
(28)
Babaei Khorzoughi R et al. / IJPR (2019), 18 (4): 1921-1930
1930
Salicornia herbacea attenuates high glucose-induced
hepatic lipogenesis in human HepG2 cells through
activation of the liver kinase B1 and silent information
regulator T1/AMPK-dependent pathway. Mol. Nutr.
Food Res. (2013) 57: 471-82.
Hou X, Xu S, Maitland-Toolan KA, Sato K, Jiang B,
Ido Y, Lan F, Walsh K, Wierzbicki M, Verbeuren TJ,
Cohen RA and Zang M. SIRT1 regulates hepatocyte
lipid metabolism through activating AMP-activated
protein kinase. J. Biol. Chem. (2008) 283: 20015-26.
Zhou G, Myers R, Li Y, Chen Y, Shen X, FenykMelody J, Wu M, Ventre J, Doebber T, Fujii N, Musi
N, Hirshman MF, Goodyear LJ and Moller DE. Role
of AMP-activated protein kinase in mechanism of
Metformin action. J. Clin. Invest. (2001) 108: 1167-74.
Horton JD, Goldstein JL and Brown MS. SREBPs:
transcriptional mediators of lipid homeostasis. Cold
Spring Harb. Symp. Quant. Biol. (2002) 67: 491-8.
Kim WS, Lee YS, Cha SH, Jeong HW, Choe SS, Lee
MR, Oh GT, Park HS, Lee KU, Lane MD and Kim JB.
Berberine improves lipid dysregulation in obesity by
controlling central and peripheral AMPK activity. Am.
J. Physiol. Endocrinol. Metab. (2009) 296: E812-9.
Liu X, Li G, Zhu H, Huang L, Liu Y, Ma C and Qin
C. Beneficial effect of berberine on hepatic insulin
resistance in diabetic hamsters possibly involves in
SREBPs, LXRα and PPARα transcriptional programs.
Endocr. J. (2010) 57: 881-93.
Downey T, Bohlen K, Callahan L, Munson V, Jahnke
M, Marshall LL, Nelson K, Huizenga P, Hansen R,
Soundy TJ and Davies GE. Lipid-lowering effect of
berberine in human subjects and rats. Phytomedicine
(2012) 19: 861-7.
Brusq JM, Ancellin N, Grondin P, Guillard R, Martin
S, Saintillan Y and Issandou M. Inhibition of lipid
synthesis through activation of AMP kinase: an
additional mechanism for the hypolipidemic effects of
berberine. J. Lipid Res. (2006) 47: 1281-8.
Zhao L, Cang Z, Sun H, Nie X, Wang N and Lu Y.
Berberine improves glucogenesis and lipid metabolism
in nonalcoholic fatty liver disease. BMC Endocr.
Disord. (2017) 17: 13.
Brusq JM, Ancellin N, Grondin P, Guillard R, Martin
S, Saintillan Y and Issandou M. Inhibition of lipid
synthesis through activation of AMP kinase: an
additional mechanism for the hypolipidemic effects of
berberine. J. Lipid Res. (2006) 47: 1281-8.
Wang H, Zhu C, Ying Y, Luo L, Huang D and Luo
Z. Metformin and berberine, two versatile drugs in
treatment of common metabolic diseases. Oncotarget
(2018) 9: 10135-46.
Kang H and Koppula S. Houttuynia cordata attenuates
lipid accumulation via activation of AMP-activated
protein kinase signaling pathway in HepG2 cells. Am.
J. Chin. Med. (2014) 42: 651-64.
Pil Hwang Y, Gyun Kim H, Choi JH, Truong Do M,
Tran TP, Chun HK, Chung YC, Jeong TC and Jeong
HG. 3-Caffeoyl, 4-dihydrocaffeoylquinic acid from
(29)
(30)
(31)
(32)
(33)
(34)
(35)
(36)
(37)
(38)
(39)
T